Inactivating mutations of CDK12 are associated with the progression and metastasis of a subset of ovarian, breast, and prostate cancers, which have been demonstrated to have a “BRCAness” phenotype with associated hypersensitivity to DNA damage agents and PARP1/2 [poly(adenosine diphosphate–ribose) polymerase 1/2] inhibitors (30–32). This evidence concerns the gene CDK12 and prostate carcinoma.